Back

Effects of sacubitril-valsartan alone or in combination with dapagliflozin on aging-related heart failure with preserved ejection fraction

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pathophysiology and mechanisms (2) Experimental Heart Failure HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Elena Mele

Naples (Italy)

7 More presentations in this session

Presentation thumbnail
Multimodal predictive model for 6-month treatment-related cardiotoxicity in non-Hodgkin lymphoma patients
Doctor D. Bursacovschi (Chisinau, MD)
Abstract Slides Video
Presentation thumbnail
Deciphering doxorubicin-induced cardiotoxicity:insights at single-cell resolution
Mr J. Van Fraeyenhove (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Takotsubo syndrome stress induced heart failure syndrome with significant LVOT obstruction
Doctor D. Kutlesic Kurtovic (Nis, RS)
Abstract Slides Video
Presentation thumbnail
Nicotinamide-N-methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model
Mr S. Li (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Evaluation of the predictive value of the HFA-ICOS score for cardiotoxicity in breast cancer patients treated with anthracyclines and trastuzumab: a real-world observational study
Doctor D. Faro (Catania, IT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pathophysiology and mechanisms (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Combination of an oral H2S donor to dapagliflozin provides additional therapeutic benefit in a cardiorenal model of heart failure with preserved ejection fraction (HFpEF)
thumbnail
Congress Presentation
Additive benefits of dapagliflozin to sacubitril/valsartan in cardiometabolic age-related cardiac dysfunction involve endothelial oxidative defense and senescence
thumbnail
Congress Session
The therapeutic conundrum in HFpEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources